Stratification of clear cell renal cell carcinoma by signaling pathway analysis

Expert Review of Proteomics

Volumn 11, Issue 2, 2014, Pages 237-249

  Cremona, Mattia ^a   Espina, Virginia ^b   Caccia, Dario ^a   Veneroni, Silvia ^a   Colecchia, Maurizio ^a   Pierobon, Mariaelena ^b   Deng, Jianghong ^b   Mueller, Claudius ^b   Procopio, Giuseppe ^a   Lanzi, Cinzia ^a   Daidone, Maria Grazia ^a   Cho, William C S ^c   Petricoin, Emanuel F ^b   Liotta, Lance ^b   Bongarzone, Italia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b GEORGE MASON UNIVERSITY   (United States)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

autophagy; HIF; hypoxia; mTOR; renal cell carcinoma; reverse phase protein array; signaling Putative biomarkers andpathway

Indexed keywords

C RAF PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN KINASE P60; PROTEIN RET; RAF PROTEIN; SCATTER FACTOR RECEPTOR; STAT PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DEATH; CELL PROLIFERATION; CELL SIGNALING ASSAY; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE DOSAGE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; STRATIFIED SAMPLE; YOUNG ADULT; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; GENE DOSAGE; HUMANS; KIDNEY NEOPLASMS; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84896985961     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.893193     Document Type: Article

References (58)

1. Drucker BJ. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 2005;31(7):536-45
2. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012. [Epub ahead of print]
3. Yagoda A, bi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22(1):42-60
4. Blanco AI, Teh BS, Amato RJ. Role of radiation therapy in the management of renal cell cancer. Cancers 2011;3(4): 4010-23
5. Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006;24(35): 5576-83
6. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22(24):4991-5004
7. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463(7279):360-3
8. Guo G, Gui Y, Gao S, et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012;44(1):17-19
9. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469(7331): 539-42
10. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56(3): 794-814
11. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005;97(6):512-23
12. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109(11):2257-67
13. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009;27(13): 2278-87
14. Brugarolas J. Renal-cell carcinoma- molecular pathways and therapies. N Engl J Med 2007;356(2):185-7
15. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006;94(5):614-19
16. Rosenberg JE, Motzer RJ, Michaelson MD, et al. Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): updated results of two phase II trials and prognostic factor analysis for survival. J Clin Oncol 2007;25:5095
17. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007;13(4): 1098-106
18. Espina V, Wulfkuhle J, Liotta LA. Application of laser microdissection and reverse-phase protein microarrays to the molecular profiling of cancer signal pathway networks in the tissue microenvironment. Clin Lab Med 2009;29(1):1-13
19. Eble JN, Sauter G, Epstein JI, et al. Pathology and genetics tumors of the urinary system and male genital organs. WHO Classification of Tumors. IARC Press; Lyon, France: 2004
20. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63
21. VanMeter AJ, Rodriguez AS, Bowman ED, et al. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 2008;7(10):1902-24
22. Espina V, Mariani BD, Gallagher RI, et al. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One 2010;54:e10240
23. Grovdal LM, Stang E, Sorkin A, Madshus IH. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 2004;300(2): 388-95
24. Williams MR, Arthur JS, Balendran A, et al. The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr Biol 2000; 10(8):439-48
25. Jo M, Stolz DB, Esplen JE, et al. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000;275(12):8806-11
26. Tang MJ, Cai Y, Tsai SJ, et al. Ureteric bud outgrowth in response to RET activation is mediated by phosphatidylinositol 3-kinase. Dev Biol 2002;243(1):128-36
27. Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal 2003;15(5):463-9
28. Guo H, Liu W, Ju Z, et al. An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci 2012;10:56
29. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006;66(13): 6589-97
30. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19): 7099-109
31. Gao N, Flynn DC, Zhang Z, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/ mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004;287(2):C281-91
32. Ma L, Chen Z, Erdjument-Bromage H, et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121(2):179-93
33. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12(1):21-35
34. Liu B, Cheng Y, Liu Q, et al. Autophagic pathways as new targets for cancer drug development. Acta Pharmacol Sin 2010; 31(9):1154-64
35. Guo A, Villen J, Kornhauser J, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008;105(2):692-7
36. Ishibe S, Karihaloo A, Ma H, et al. Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development 2009;136(2): 337-45
37. Liu L, Cash TP, Jones RG, et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 2006;21(4):521-31
38. Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, et al. Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia. Mol Cell Biol 2011; 31(9):1870-84
39. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14(6):435-46
40. Baldewijns MM, van VI, Vermeulen PB, et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010;221(2):125-38
41. Toschi A, Lee E, Gadir N, et al. Differential dependence of hypoxia-inducible factors 1 alpha and alpha on mTORC1 and mTORC2. J Biol Chem 2008;283(50):34495-9
42. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66(3):1500-8
43. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12(1):9-22
44. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010;29(26): 3733-44
45. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. A genomescale effort that mapped significantly mutated pathways in human cancer through network projection of mutational profiles, leading to the identification of novel disease mechanisms. Nature 2013;499:43-9
46. Gunawan B, Huber W, Holtrup M, et al. Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res 2001;61(21):7731-8
47. Zhang Z, Wondergem B, Dykema K. A Comprehensive Study of progressive cytogenetic alterations in clear cell renal cell carcinoma and a new model for ccRCC tumorigenesis and progression. Adv Bioinformatics 2010;428325
48. Tang MH, Tan J, Cui FL. [Expression of pituitary tumor transforming gene in human renal clear cell carcinoma and its significance]. Nan Fang Yi Ke Da Xue Xue Bao 2010;30(7):1712-14
49. Wondergem B, Zhang Z, Huang D, et al. Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma. Cancer Res 2012;72(17): 4361-71
50. Chen ZH, Lam HC, Jin Y, et al. Autophagy protein microtubule-associated protein 1 light chain-3B (LC3B) activates extrinsic apoptosis during cigarette smoke-induced emphysema. Proc Natl Acad Sci USA 2010;107(44):18880-5
51. Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y. Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol 2009;10(7):458-67
52. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest 2005; 115(10):2679-88
53. Komatsu M, Waguri S, Ueno T, et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol 2005;169(3):425-34
54. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007;7(12):961-7
55. Qayyum T, McArdle P, Orange C, et al. Reclassification of the Fuhrman grading system in renal cell carcinoma-does it make a difference? SpringerPlus 2013;2:378
56. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010;6(3):322-9
57. Sun SY. Enhancing perifosine's anticancer efficacy by preventing autophagy. Autophagy 2010;6(1):184-5
58. STRING - known and predicted protein-protein interactions. Available from: http://string-db.org/